Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

The discussion will focus on Numinus’ CRO activities conducted by Cedar Clinical Research (CCR); CCR growth and initiatives; and the new Phoenix, Arizona clinical research site.

For all investors and other persons interested in participating, please register here.

For more information about the event, or to schedule a one-on-one meeting with Numinus’ management, please send an email to invest@numinus.com.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental healthcare and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.